GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update

GenSight Biologics on Track to Submit LUMEVOQ® for European Approval in September 2020 Following Pre-Submission Meeting with EMA

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa

Annual General Meeting on April 29, 2020 Procedures for obtaining preparatory documents for the General Meeting

GenSight Biologics Announces the Filing of its 2019 Universal Registration Document

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics Reports Full Year 2019 Financial Results and provides an Outlook on 2020

GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS

GenSight Biologics Reports its Cash Position as of December 31, 2019 and Provides Operational Update